Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Fisogatinib (BLU-554)
Fisogatinib · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Fisogatinib (BLU-554) | EXPERIMENTAL | Fisogatinib (BLU-554) capsules for oral administration. |
| Name | Type | Description |
|---|---|---|
| Fisogatinib (BLU-554) | DRUG | - |
Key Inclusion Criteria: * Confirmed diagnosis of HCC by histological examination or by non-invasive criteria according to European Association for the Study of the Liver (EASL) or American Association for the Study of Liver Disease (AASLD) guidelines (Part 1, 2 and 3). * For Part 1 and 2, the patie...
Fisogatinib is an investigational small molecule being studied for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. It is being developed as an oral therapy for patients with this condition and has been evaluated in a Phase 1 clinical study.
Fisogatinib is a kinase inhibitor, belonging to the -tinib class of small molecule drugs. Kinase inhibitors work by blocking specific enzymes that drive cancer cell growth and survival. Fisogatinib is designed to inhibit its kinase target in the context of hepatocellular carcinoma.
Fisogatinib is being developed by Blueprint Medicines Corporation, a biopharmaceutical company that trades under the ticker symbol BPMC. Blueprint Medicines focuses on precision therapies for cancer and other diseases, and fisogatinib is part of its oncology pipeline.
Fisogatinib is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The Phase 1 study evaluating fisogatinib in hepatocellular carcinoma has been completed.
Fisogatinib has been evaluated in a Phase 1 study, NCT02508467, titled A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma. The trial enrolled 146 patients across the United States, China, France, Germany, Hong Kong, Italy, Singapore, South Korea, Spain, Switzerland, Taiwan, and the United Kingdom, and it is now completed.
Yes, fisogatinib is also known as BLU-554. Both names refer to the same investigational small molecule developed by Blueprint Medicines Corporation for hepatocellular carcinoma. The Phase 1 trial NCT02508467 lists the drug under the name fisogatinib (BLU-554).